Phase 1 Rheumatoid arthritis trials recruiting now

All Rheumatoid arthritis trials, every phase

Other phases for Rheumatoid arthritis

Phase 1 Rheumatoid arthritis trials

• A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
  NCT07363590 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 21 locations
• A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
  NCT07413341 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
  NCT06978647 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A First-in-human Study of KT501 Administered Subcutaneously to Patients With Rheumatoid Arthritis (RA).
  NCT07234773 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)
  NCT07564154 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
  NCT07284797 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase 1 Study of ADI-001 in Rheumatoid Arthritis
  NCT07100873 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
  NCT07533955 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 3 locations
• A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases
  NCT07712939 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
  NCT06733935 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 18 locations
• A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
  NCT07230353 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
  NCT06946641 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 22 locations
• A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
  NCT07412704 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 39 locations
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis
  NCT06994143 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease
  NCT07041099 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
  NCT07245992 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
• A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
  NCT06857227 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
  NCT07371468 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 19 locations
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
  NCT07115745 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)
  NCT06917742 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
  NCT07258849 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07276958 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 9 locations
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07607964 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
  NCT06977724 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 11 locations
• A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
  NCT07048197 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 12 locations
• A Study to Assess the Safety and Tolerability of SR-878 in Patients With Rheumatoid Arthritis
  NCT07433335 · Phase: Phase 1 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 4 locations
• A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
  NCT05638854 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases
  NCT06647069 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis
  NCT07171983 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 9 locations
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
  NCT06916806 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 37 locations
• An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
  NCT07236762 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
  NCT06946199 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT
  NCT07062523 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
  NCT07040930 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
  NCT07361094 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 2 locations
• Controlling Hyperactive Immunity With Long-lived Lymphocytes
  NCT07473154 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
  NCT06392711 · Phase: Phase 1 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
  NCT06801119 · Phase: Phase 1 · Ages: 18 Years to 69 Years · Sex: All (male and female) · 1 location
• Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
  NCT07236801 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 2 locations
• FT839 in Autoimmune Diseases
  NCT07800871 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Fexofenadine in Patients With Active Rheumatoid Arthritis
  NCT05264025 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 2 locations
• Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  NCT06350110 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Imaging of Lymphatic Vessels in People With Rheumatoid Arthritis (RA)
  NCT05197530 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intraglandular Treatment With Adipose-derived Mesenchymal Stem Cells in Patients With Xerostomia Due to Sjögren's Disease
  NCT06805448 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye
  NCT06543667 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
  NCT06581562 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
  NCT07085676 · Phase: Phase 1 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 2 locations
• Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
  NCT07237659 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 7 locations
• Phase 1b/2 Study of IV Sarilumab in Adult With RA
  NCT07704580 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• R-2487 in Patients With Rheumatoid Arthritis
  NCT05961592 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
  NCT06056921 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
  NCT06828042 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
  NCT06628206 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for RA
  NCT05003934 · Phase: Phase 1 · Ages: No age limits stated · Sex: All (male and female) · 2 locations
• Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants
  NCT07182656 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location
• Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
  NCT06428188 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 90 Years · Sex: All (male and female) · 1 location
• Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
  NCT07201558 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 34 locations
• Study of GS-0151 in Participants With Rheumatoid Arthritis
  NCT06902519 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 35 locations
• Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis
  NCT07207954 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 7 locations
• Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
  NCT07455578 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 6 locations
• Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
  NCT06201416 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 9 locations
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 260 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.